BioPark Annual report 2024
The current development of life science companies in the BioRegio Regensburg shows a consolidation two years after the official end of the Corona pandemic in a proportion of the companies. The number of companies increased slightly while the number of employees also fell slightly. The new business figures for 2024 presented by BioPark Regensburg GmbH show 67 companies and 5,648 employees for the cluster in Eastern Bavaria.
At the beginning of the year, the industry association BIO Deutschland e.V. reported that the financing of German biotechnology companies increased significantly by 78% in 2024 compared to the previous year. Positive news after the capital market collapsed after the pandemic. This had consequences not only for the equity-financed companies, but also for their suppliers and contract researchers. In BioRegio Regensburg, the annual survey of the cluster's companies from the fields of biotechnology, pharmaceuticals and medical engineering, diagnostics, analytics and the healthcare industry in Eastern Bavaria shows a heterogeneous picture. The total number of companies in the cluster rose slightly compared to the previous year to 67 companies (+ 1). The total number of employees, however, fell slightly from 5,671 to 5,648 (- 0.5%) (see graph 1).
The BioPark is currently 90% occupied. The technology and start-up center currently accommodates 34 teaseholders with 596 employees in its three buildings on a gros area of 18,000 m2. BioPark GmbH's turnover in 2024 was around €5 million.
Currently in the BioRegio Regensburg cluster there are 8 pharmaceutical companies (+ 2) with 1,862 employees (+242), 31 medtech companies from the medical engineering industry (-1) , diagnostics & analytics with 3,054 employees (- 89) and 28 biotech companies (+1) with 732 employees (- 167) in comparison to the previous year (see graph 2).
For BioPark Managing Director Dr. Thomas Diefenthal , the picture is clear. After the boom of the Corona years, the consolidation of the life science scene has continued in the BioRegio Regensburg in 2024. The current development of the pharmaceutical industry at the site is encouraging, as it has been able to compensate for a large part of the losses. Biotechnology is an important growth market that offers Germany great opportunities. Many companies are active in disease areas with high medical needs such as cancer, autoimmune diseases and neurode generative diseases. With groundbreaking technologies such as radiopharmaceuticals, antibody-drug conjugates or gene scissors, the biotech indust also has an excellent position technologically speaking in BioRegio Regensburg.
With the Healthcare Regensburg - managed by BioPark initiative, the city of Regensburg wants to use and promote the opportunities in the healthcare industry for our society and region. The network, founded in 2017 with the Masterplan Healthcare Regensburg, includes companies, universities, vocational schools, hospitals, research, start-ups and other partners from the healthcare industry in the region and is enjoying increasing popularity. After initially having 80 players, there are now 131 network partners active here, as cluster manager Dr. Ilja Hagen reports (see graph 3).
For more details see under https://www.biopark-regensburg.de/en/home